Endocrine Today Current Issue

The following articles appeared in the print edition of Endocrine Today.

Table of Contents

• Beyond diabetes, metformin may prove to be a ‘wonder drug’ Regina Schaffer
• Court grants injunction to prevent US sales of alirocumab due to patent infringement
• A conversation with Donna Ryan, MD
• Group supports patients with familial chylomicronemia syndrome James Falko, MD
• Eggshell calcification of thyroid nodule not always benign Sung Hye Kong, MD; Stephanie L. Lee, MD, PhD, ECNU
• AACE: CVD ‘extreme risk’ category introduced in updated lipid guidelines
• Calcium, vitamin D, HT combination improves LDL in postmenopausal women
• Childhood GH treatment does not increase adulthood diabetes risk
• Combined testosterone therapy, weight loss improves androgen deficiency in men with obesity
• Computer-aided thyroid nodule diagnosis demonstrates sensitivity similar to radiologists
• Current sulfonylurea, TZD use increases fracture risk in type 2 diabetes
• Education, planning improvements needed for pediatric diabetes patients transitioning to adult care
• Excess enterovirus infections observed in children with type 1 diabetes
• GH therapy alters circulating thyroid hormones, deiodinase activity in men
• GH therapy does not affect glucose homeostasis in adults
• GH treatment safe, effective in Silver-Russell syndrome
• Guidelines needed to address iodine supplementation in pregnancy
• High-deductible insurance associated with delayed care in diabetes
• HT for menopausal symptoms benefits bone health
• Hypothalamic pituitary conditions may hinder social milestone achievement
• Intensity of physical activity linked to musculoskeletal health in middle-aged women
• Interrupting sitting time with walking, standing improves glycemic control in type 2 diabetes
• Lanreotide not harmful for HbA1c, lipid levels in acromegaly
• Metabolic syndrome tied to cognitive impairments in adolescents
• Metformin increases A. muciniphila in patients with type 2 diabetes
• Need, timing of surgery must be weighed against potential benefits in MEN1
• No increased risk for death in ‘metabolically healthy’ adults with obesity
• Pioglitazone increases absolute fracture risk in prediabetes treatment
• Sclerostin levels not associated with type 2 diabetes risk
• Short sleep duration increases hyperglycemia risk among inpatients
• Sugar-sweetened beverages associated with short sleep in adults
• Teriparatide fails to heal atypical femur fractures, despite improved bone quality
• Transgender health care lacks multidisciplinary training
• TSH levels may predict postoperative hypothyroidism
• Weight loss at 1 year predicts sustained benefit, lower HbA1c in diabetes, obesity
• Experts, patients come together to address barriers to PCSK9 inhibitor access
• Should metformin be the first-line therapy choice in type 2 diabetes treatment?
• Addressing cognitive impact of hyperglycemia on diabetes self-management Eliot LeBow, LCSW, CDE